MMCAP International Inc. SPC Reports 17.9% Stake in Cardiol Therapeutics Inc. via 13G/A Filing

MMCAP International Inc. SPC, along with its investment adviser MM Asset Management Inc., has filed an amended Schedule 13G (Amendment No. 1) regarding its holdings in Cardiol Therapeutics Inc. (CRDL). As of the event date on March 31, 2026, the reporting persons disclosed beneficial ownership of 21,063,856 Class A Common Shares, representing a 17.9% stake in the company. This position includes 15,352,317 directly held shares and 5,711,539 shares underlying warrants exercisable within 60 days. The filing indicates a significant increase from a previous ownership level of 0.0%, effectively establishing a major reporting position. The reporting persons have shared voting and dispositive power over the securities. The filing was made under Rule 13d-1(c), certifying that the shares were not acquired for the purpose of influencing or changing control of the issuer. The total outstanding share count used for the percentage calculation was 111,872,084, as reported in the issuer's recent financial disclosures.